These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17440637)

  • 21. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.
    Cox R; Krupnick J; Bush N; Houpt A
    J Miss State Med Assoc; 2000 Aug; 41(8):690-2. PubMed ID: 10974795
    [No Abstract]   [Full Text] [Related]  

  • 24. Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.
    Cowles BJ
    Ann Pharmacother; 2009 Apr; 43(4):669-76. PubMed ID: 19318601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADHD and stimulant drug treatment: what can the children teach us?
    Erler A
    J Med Ethics; 2013 Jun; 39(6):357-8. PubMed ID: 23689793
    [No Abstract]   [Full Text] [Related]  

  • 28. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symposium: behavior modification by drugs. II. Psychological effects of stimulant drugs in children with minimal brain dysfunction.
    Conners CK
    Pediatrics; 1972 May; 49(5):702-8. PubMed ID: 4402496
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA; Alperin S; Leon T; Faraone S
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
    Dupaul GJ; Weyandt LL; Rossi JS; Vilardo BA; O'Dell SM; Carson KM; Verdi G; Swentosky A
    J Atten Disord; 2012 Apr; 16(3):202-20. PubMed ID: 22166471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials.
    Surman CB; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):903-8. PubMed ID: 21824454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.
    Bruno C; Zoega H; Gillies MB; Havard A; Coghill D; Pearson SA; Brett J
    Aust N Z J Psychiatry; 2023 Jul; 57(7):1073-1076. PubMed ID: 37122132
    [No Abstract]   [Full Text] [Related]  

  • 35. [Stimulant therapy in children].
    Steinhausen HC
    Pharmacopsychiatria; 1982 Nov; 15(6):181-2. PubMed ID: 6130534
    [No Abstract]   [Full Text] [Related]  

  • 36. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
    J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 38. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
    Airaksinen E; Airaksinen MM
    Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
    [No Abstract]   [Full Text] [Related]  

  • 39. [Substitution of dexamethasone for dexamphetamine due to their written and spoken similarity].
    Hoppenbrouwers CJ; Mooren GC; van den Heuvel JJ; Op de Coul ME; van Trotsenburg PA
    Ned Tijdschr Geneeskd; 2010; 154():A1662. PubMed ID: 20858310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to Calver et al. on the WA regulatory scheme for stimulants.
    Stevens M
    Aust N Z J Public Health; 2008 Apr; 32(2):182. PubMed ID: 18412693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.